A phase 2 clinical trial testing the ability of BCG vaccine to reverse advanced type 1 diabetes has received approval from FDA.
The five year human trial will investigate whether BCG vaccination can clinically improve type 1 diabetes between 18 and 60 years of age who have small but still detectable levels of insulin secretion from pancreas,
In phase 1 clinical trials( published 2012 ) provided evidence of a small transient return of insulin secretion.